Discover 2 promising assets, which will revolutionize the therapeutic treatment in neurodegenerative diseases. They are looking for industrial partners to bring them to clinical stage!
These programs, named ATK and DELIS, come from renowned public research laboratories in France.
ATK and DELIS programs have generated NCE that open up a therapeutic pathway for neurodegenerative pathologies without any therapeutic solution to date:
- DISEASES TARGETED:
Neurodegenerative diseases, especially:
- Alzheimer's disease
- Huntington's disease (ATK)
- ALS et CIAS (DELIS)
- MECHANISM OF ACTION:
- ATK > TrkB PAM (Positive Allosteric Modulator) / first in class
- DELIS > agoniste sigma1 / best in class potential
- hit to lead opportunity (SAR and first optimization round)
- in vitro caracterization ADME/TOX
- PK et in vivo tox profile
- in vivo POC
+++ NCE, first and best in class
+++ Strong potential in orphan diseases with no therapeutic solutions
+++ Patented and derisked
+++ Wide application potential
ARE YOU A STARTUP, A BIOTECH COMPANY OR A BIG PHARMA ?
YOU CAN :
- take a licence for both molecules or only one
- benefit from an exclusive and worlwide exploitation rights
- connect and collaborate directly with the researchers-inventors, experts in the targets
The licensing process of these technologies will be fully managed by SATT CONECTUS (French TTO). You will have a single point of contact throughout the transfer process.